Quantcast
Last updated on April 23, 2014 at 13:51 EDT

Latest autoimmune disease Stories

2012-11-29 08:29:36

SUMMIT, N.J., Nov. 29, 2012 /PRNewswire/ -- Protalex, Inc. (OTCBB:PRTX), a clinical stage biopharmaceutical company, today announced enrollment and dosing of the first patient in the U.S. for its new multicenter Phase 1b randomized, multiple-dose, dose-escalation study of PRTX-100 in adults with active rheumatoid arthritis (RA). Protalex is focused on the development of a class of drugs designed to treat autoimmune and inflammatory diseases including RA. The primary objective of this Phase...

2012-11-21 06:20:29

This discovery holds the potential to reduce healthcare costs for many common inflammatory diseases such as cancer and diabetesSingapore, Nov 21, 2012 - (ACN Newswire) - A*STAR scientists have identified the enzyme, telomerase, as a cause of chronic inflammation in human cancers. Chronic inflammation is now recognized as a key underlying cause for the development of many human cancers, autoimmune disorders, neurodegenerative diseases, and metabolic diseases such as diabetes. This enzyme,...

2012-11-19 12:34:05

NIH-funded scientists develop new treatment to combat autoimmune disease in mouse model In a mouse model of multiple sclerosis (MS), researchers funded by the National Institutes of Health have developed innovative technology to selectively inhibit the part of the immune system responsible for attacking myelin–the insulating material that encases nerve fibers and facilitates electrical communication between brain cells. Autoimmune disorders occur when T-cells–a type of white...

2012-11-19 11:38:02

New nanotechnology can be used for Type 1 diabetes, food allergies and asthma -New nanoparticle tricks and resets immune system in mice with MS -First MS approach that doesn't suppress immune system -Clinical trial for MS patients shows why nanoparticle is best option -Nanoparticle now being tested in Type 1 diabetes and asthma In a breakthrough for nanotechnology and multiple sclerosis, a biodegradable nanoparticle turns out to be the perfect vehicle to stealthily deliver an antigen...

2012-11-15 08:32:08

NEW YORK, Nov. 15, 2012 /PRNewswire/ -- TNI BioTech, Inc. (Pinksheets: TNIB) announced today the signing of an exclusive distributor agreement with G-Ex Technologies/St. Maris Pharma & GB Pharma Holdings LLC for the Federal Republic of Nigeria. Under the terms of the agreement, G-Ex Technologies/St. Maris Pharma & GB Pharma Holdings LLC will have exclusive marketing and distribution rights to IRT-103 LDN and IRT-104 LDN cream in Nigeria. TNIB will be responsible for the...

2012-11-08 16:27:14

SUMMIT, N.J., Nov. 8, 2012 /PRNewswire/ -- Protalex, Inc. (OTCBB: PRTX), a clinical stage biopharmaceutical company, today announced that it has begun screening patients at sites in the U.S. for its new multicenter Phase 1b randomized, multiple-dose, dose-escalation study of PRTX-100 in adults with active rheumatoid arthritis (RA). Protalex is focused on the development of a class of drugs designed to treat autoimmune and inflammatory diseases including RA. The primary objective of this...

2012-11-08 08:34:58

SAN DIEGO and WASHINGTON, Nov. 8, 2012 /PRNewswire/ -- aTyr Pharma, an innovator in immune-modulating protein therapeutics, announced today their presentation at the 2012 American College of Rheumatology (ACR) / Association of Rheumatology Health Professionals (ARHP) Annual Meeting, which is being held November 9-14 in Washington, D.C. The presentation provides an in-depth molecular characterization of Jo-1 antibodies, which occur as part of a rare, human autoimmune response to histidyl tRNA...

2012-10-18 07:26:08

SUMMIT, N.J., Oct. 18, 2012 /PRNewswire/ -- Protalex, Inc. (OTCBB: PRTX), a clinical stage biopharmaceutical company, today announced that its abstract on results from the recently completed PRTX-100 Phase 1b randomized, multiple-dose, dose-escalation study in South Africa of PRTX-100 has been accepted for oral presentation at the American College of Rheumatology (ACR) 2012 Annual Meeting to be held in Washington D.C. November 9-14. Protalex is focused on the development of a class of drugs...

2012-10-16 11:25:42

GLEN ALLEN, Va., Oct. 16, 2012 /PRNewswire/ -- Star Scientific, Inc. (NASDAQ: STSI) through its wholly owned subsidiary, Rock Creek Pharmaceuticals Inc., reports that earlier in the week scientists from its research partner, the Roskamp Institute, presented results of its recent research showing that anatabine supplementation significantly reduces central and peripheral inflammation and neurological injury in an animal model of multiple sclerosis (MS). The findings were presented in New...

2012-10-15 11:25:26

Reproducing a rare type of B cell in the laboratory and infusing it back into the body may provide an effective treatment for severe autoimmune diseases such as multiple sclerosis or rheumatoid arthritis, according to researchers at Duke University Medical Center. The findings, which were demonstrated in mice, highlight the unique properties of a subset of B cells that normally controls immune responses and limits autoimmunity, in which an organism mistakenly attacks its own healthy...